Equities

Next Science Ltd

Next Science Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.33
  • Today's Change0.01 / 3.13%
  • Shares traded15.58k
  • 1 Year change-48.44%
  • Beta1.8925
Data delayed at least 20 minutes, as of May 03 2024 07:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Next Science Limited is an Australia-based medical technology company. The Company’s primary focus is on the development and commercialization of its proprietary XBIO technology to reduce the impact of biofilm-based infections on human health. XBIO is a non-toxic technology with an efficacy in eradicating both biofilm-based and free-floating bacteria. The Company’s products include XPERIENCE, Blast X, SurgX and Bactisure. The XPERIENCE product is an antimicrobial solution used to prevent surgical site infections by rinsing away debris and microorganisms. SurgX Sterile Antimicrobial Gel is used to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-based bacteria within the gel with sustained effectiveness for up to five days. BLASTX Antimicrobial Wound Gel provides wound management by maintaining a moist wound environment, which is conducive to wound healing.

  • Revenue in AUD (TTM)33.79m
  • Net income in AUD-24.79m
  • Incorporated2017
  • Employees--
  • Location
    Next Science LtdTower BThe Zenith L 19, 821 Pacific HighwayChatswood 2000AustraliaAUS
  • Phone+61 28607-5124
  • Websitehttps://www.nextscience.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Starpharma Holdings Ltd10.63m-8.40m49.44m50.00--1.43--4.65-0.0205-0.02050.02590.08370.20920.2822.10---16.53-28.47-20.70-33.6692.6771.62-79.00-391.825.22--0.0833---14.10-3.223.19--11.58--
Anteotech Ltd526.75k-11.46m50.58m40.00--9.71--96.02-0.0056-0.00560.00030.00220.0552--2.62---120.11-68.55-145.22-75.44-----2,176.15-1,432.10----0.1729---46.6511.41-18.08--25.84--
Biome Australia Ltd10.24m-2.86m59.59m30.00--27.64--5.82-0.0141-0.01410.05060.01011.371.936.04341,434.70-38.27---74.60--61.29---27.97--0.9514-15.920.4032--73.58--32.20------
Percheron Therapeutics Ltd624.51k-10.85m69.42m8.00--4.22--111.16-0.0157-0.01570.00090.01820.0328--0.3224---56.94-72.09-66.58-81.73-----1,737.37-6,558.90----0.001--1,026.1672.03-95.81------
Argenica Therapeutics Ltd92.21k-4.67m71.85m----8.80--779.18-0.0511-0.05110.0010.06650.0109--0.6384---55.31---69.00-------5,067.62-----6,663.200.00--2,340.00---17.71------
Vitura Health Ltd119.67m9.40m71.98m121.007.591.8319.040.60150.01650.01650.20990.06811.9811.2210.51989,034.2015.2515.2922.3021.0631.23--7.706.921.185,598.190.2359--75.16--128.31146.9554.86--
Actinogen Medical Ltd337.51k-14.87m74.46m----6.16--220.62-0.0074-0.00740.00020.00520.0211--0.7341---92.99-45.55-105.88-48.24-----4,405.86-5,369.76---294.930.0037--792.7431.88-13.21--166.95--
Orthocell Ltd6.06m-7.42m82.68m----36.13--13.65-0.0369-0.03690.03010.01090.21821.5027.68---26.73-32.67-31.96-38.5377.1163.04-122.55-374.464.36--0.2586--215.2451.5331.39--11.07--
Paradigm Biopharmaceuticals Ltd8.67m-69.00m85.70m----2.55--9.89-0.2296-0.22960.02880.09620.1298--2.25---103.34-40.96-127.58-44.1399.87---796.30-466.85---348.760.0085--7.5825.42-32.26------
PharmAust Limited1.85m-7.79m86.90m52.00--11.03--46.95-0.0236-0.02010.00550.020.1977--6.71---83.26-25.56-96.46-28.7820.0690.73-421.04-59.16---104.650.00---13.533.42-263.63---47.47--
Next Science Ltd33.79m-24.79m96.26m----4.93--2.85-0.1072-0.10720.14440.0671.467.478.33---107.19-74.40-136.06-90.3173.2076.98-73.36-128.263.45-50.370.0698--89.3650.80-28.29---2.28--
Vita Life Sciences Limited74.16m9.08m125.98m124.0013.612.9413.141.700.1660.1661.360.76951.332.347.35--16.2715.2522.5121.9958.1460.9012.2411.712.29--0.008939.0510.8812.5028.1830.0712.1519.14
Recce Pharmaceuticals Ltd6.81m-11.32m130.53m----244.05--19.16-0.0637-0.06370.03850.00261.68--52.84---279.04-110.82-985.91-139.61-----166.11-391.79---24.070.2712--39.5327.79-19.03---26.31--
Arovella Therapeutics Ltd139.02k-10.23m136.52m14.00--37.74--982.02-0.0127-0.01270.00020.00340.0249--15.15---182.82-77.12-276.07-93.2683.5663.41-7,357.19-1,471.57----0.00--45.470.3491-18.11---68.72--
Proteomics International LaboratoriesLtd1.44m-5.90m137.44m----24.00--95.12-0.0518-0.05180.01290.04370.1817--11.13---75.75-57.79-87.11-67.57-----416.78-229.69---283.470.0088---14.644.12-24.20--89.02--
Data as of May 03 2024. Currency figures normalised to Next Science Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

0.98%Per cent of shares held by top holders
HolderShares% Held
Endeavor Asset Management Pty Ltd.as of 14 Mar 20232.85m0.98%
Data from 24 Aug 2023 - 24 Aug 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.